TACE for liver cancer
Transarterial chemoembolization (TACE) delivers chemotherapy directly into the artery that feeds a liver tumour. The artery is then blocked so the drug stays in the tumour. Two forms exist: conventional TACE with an oil-based mix, and drug-eluting bead TACE (DEB-TACE).
Who it may suit
- Hepatocellular carcinoma that cannot be removed or ablated, especially intermediate stage (BCLC B)
- Liver function that is still good enough to tolerate treatment
- Cancer mainly in the liver, without a blocked main portal vein
What happens
- Review of liver scans, liver function and your overall health
- Catheter placed through an artery to the liver tumour
- Chemotherapy and blocking particles delivered, usually in 60 to 90 minutes
- Hospital stay for pain and nausea control, then scans to judge response
About 3 to 7 days per session in hospital.
TACE is widely available in Canada through liver and interventional radiology teams, usually with a short wait.
How it works
TACE is one of the most widely used treatments for liver cancer that cannot be cured by surgery or ablation. In the BCLC staging system it is the standard option for intermediate-stage (B) hepatocellular carcinoma. The tumour gets most of its blood from the hepatic artery, while healthy liver gets much of its blood from the portal vein. That difference is what TACE uses.
In conventional TACE, the chemotherapy is mixed with an oily contrast agent and then particles block the artery. In DEB-TACE, the drug is carried on tiny beads that release it slowly. The National Cancer Institute notes that beads may cause fewer chemotherapy side effects, but that overall survival benefit was shown in only one study. Radiology sources report that TACE slows or shrinks tumours in about two-thirds of patients, for an average of 10 to 14 months, and it can be repeated.
China has treated very large numbers of patients with TACE, and many studies come from Chinese teams. These include TACE combined with ablation, radiotherapy or targeted and immune drugs. Some reports suggest better results with combinations, but study designs vary and guideline groups are still weighing them. Combinations can also add side effects. Decisions should be made with your own liver specialist. TACE can be risky in patients with poor liver function, jaundice or a blocked portal vein.
Potential advantages
- Treats the tumour while sparing much of the healthy liver
- Can be repeated if the tumour returns or new areas appear
- Can be combined with ablation or drug treatment in some patients
- Done through a small puncture, without open surgery
- Experienced centres may treat many cases a year
What to prepare for a specialist review
- CT or MRI scans of the liver, with image files
- Liver function tests, bilirubin, clotting and alpha-fetoprotein levels
- Hepatitis B or C status and cirrhosis history
- Details of any earlier TACE, ablation, surgery or drug treatment
- Kidney function and any contrast dye allergy
- Your Canadian oncologist's current treatment plan
Questions to ask the treating team
- Is conventional TACE or DEB-TACE better for my tumour, and why?
- Would you combine TACE with ablation or drug treatment, and what is the evidence?
- How is my liver function judged to be safe enough?
- How many sessions might I need, and when would we change plan?
- Can I receive the same treatment in Canada, and how soon?
Things to know. Many people have fever, pain and nausea for several days. Serious complications such as liver failure occur in a small number of patients. TACE controls tumours but is not a cure. We are still confirming which Chinese hospitals currently offer this to international patients.
Why an introduction matters
Many of China’s leading specialists work in busy public hospitals without international patient offices. They rarely answer enquiries from abroad directly, and a file sent without an introduction often goes unread. Cases usually reach them through people they already know and trust. Our team on the ground makes that introduction, presents your case properly in Chinese, and follows up until you have an answer.
Related pages
Sources: RadiologyInfo.org (RSNA and ACR): Chemoembolization · National Cancer Institute: Adult primary liver cancer treatment (PDQ)
Last reviewed: 12 November 2026. This page is general information, not medical advice.
Some programmes, especially stem-cell and other cell treatments, are experimental. We introduce them only if you ask and your own specialist agrees, and we never describe them as cures.